+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Surgical Stage I high-grade ovarian cancer: is adjuvant chemotherapy warranted?



Surgical Stage I high-grade ovarian cancer: is adjuvant chemotherapy warranted?



European Journal of Gynaecological Oncology 36(6): 633-636



To review the results of patients with high-grade Stage I ovarian cancer managed without adjuvant treatment. A retrospective chart review identified patients with newly diagnosed Stage I high-grade ovarian cancer, who underwent comprehensive surgical staging. Thirty-three patients with FIGO surgical Stage I high-grade ovarian cancer were identified. After a median follow-up of 40 months, nine patients (27%) recurred. The median time to recurrence was 19 months. Of the nine patients with recurrences, four (44%) are alive with disease, three (33%) patients have no evidence of disease, and two have died of disease (22%). The two- and five-year overall survival is 100% and 90%, respectively. It would appear the recurrence rates of Stage I high risk epithelial ovarian cancer completely staged, without adjuvant treatment are comparable to those of treatment arms reported in the literature. A proportion of these patients can be salvaged at recurrence, yielding a high overall survival.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058940798

Download citation: RISBibTeXText

PMID: 26775342


Related references

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. Journal of the National Cancer Institute 95(2): 113-125, January 15, 2003

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer. Gynecologic Oncology 2019, 2019

No survival benefit with adjuvant chemotherapy in nonserous stage IB grade 2 epithelial ovarian cancer. Gynecologic Oncology 141: 53-54, 2016

Adjuvant chemotherapy beneficial for select early-stage, low-grade serous ovarian cancer patients. Gynecologic Oncology 141: 187-188, 2016

Adjuvant chemotherapy for high-stage and/or high-grade bladder cancer following radical cystectomy. A preliminary report. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 77(3): 466-473, 1986

Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?. Gynecologic Oncology 144(2): 238-240, 2016

'Moderate-risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation. International Journal of Gynecological Cancer 4(4): 272-278, 1994

Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?. International Journal of Gynecological Cancer 20(7): 1125-1131, 2011

The role of pelvic and aortic lymphadenectomy at second look surgery in apparent early stage ovarian cancer after inadequate surgical staging followed by adjuvant chemotherapy. Gynecologic Oncology 132(2): 312-315, 2014

The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer. Archives of Gynecology and Obstetrics 295(2): 451-458, 2016

Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Annals of Oncology 11(3): 281-288, 2000

Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. International Journal of Gynecological Cancer 11(Supplement S1): 20-20, 2001

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. Yonsei Medical Journal 59(8): 930-936, 2018

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Journal of Ovarian Research 9(1): 85, 2017

ACTION+ICON1 Two parallel randomised phase III trials comparing adjuvant chemotherapy to no adjuvant chemotherapy following surgery in women with high risk early ovarian cancer. European Journal of Cancer 37(Supplement 6): S276, 2001